Top Series C AI companies

Lightship is a clinical trial site organization delivering on-site, hybrid, and virtual trials through a single, trusted partner. Our expanded reach model places each visit in the most practical setting, increasing access, strengthening enrollment and engagement, and improving representation across diverse communities.Our investigators and study teams follow participants across all visit types, supported by a unified SOP framework and shared technology backbone. This continuity preserves oversight, streamlines study conduct, and gives sponsors auditable visibility across the entire participant journey.With a growing footprint of eight physical sites and mobile research units (MRUs) that extend site capabilities into the community, Lightship increases access for participants who might otherwise be out of reach. Our 96 percent retention rate, 30-plus sponsor audits, and multiple FDA engagements reflect a strong quality record that gives sponsors confidence in a reliable path to high-performing trial execution.We’re building trial experiences that reflect real life: expanding reach, reducing burden, and bringing better therapies to market faster.

• Series C
• 59 employees
• Founded 2018

ModelBest established in August 2022, is an Artificial Intelligence technology company headquartered in Beijing, China. The company is deeply rooted in the field of general AI, with a focus on the innovation and application transformation of large-scale models. ModelBest boasts a prestigious founding R&D team from the Tsinghua in the AI field. Leveraging numerous cutting-edge technologies in natural language processing, the company is currently constructing a large-scale pre-trained model library and corresponding tools, aiming to standardize the technology and applications of large models. Based on the capabilities of the CPM series of large models, ModelBest has successfully facilitated the intelligent upgrade and efficiency enhancement of various industries. Moreover, the company has released a multi-modal dialog assistant with hundreds of billions of parameters, “Luca", to the public. Adhering to the core philosophy of "intelligence encompassing all", we look forward to exploring and expanding unknown possibilities with global partners, aiming to ensure AI technology serves humanity for a better life in a safe and inclusive manner, laying a solid foundation for the advent of the AGI world.OpenBMB (Open Lab for Big Model Base,https://github.com/OpenBMB), founded by ModelBest Inc & TsinghuaNLP, aims to build foundation models and systems towards AGI.

• Series C
• 45 employees
• Founded 2022

Certis Oncology is transforming how oncology R&D decisions are made.Through Certis Oncology Intelligence®, our AI-powered translational decision intelligence platform, we help biopharma organizations generate data-driven insights into therapeutic response, identify biomarkers, prioritize experiments, and accelerate drug development.Traditional drug development generates vast amounts of scientific data, yet much of that knowledge remains fragmented across studies, teams, and systems. Certis Oncology Intelligence® is designed to help organizations unlock the full value of those data assets by integrating predictive intelligence, agentic data exploration, and experimental validation into a unified decision intelligence ecosystem.The platform combines:• CertisAITM — a predictive intelligence engine that leverages relationships between drug chemistry and tumor biology to generate insights into therapeutic response• Agentic Data Ecosystems — secure, sponsor-specific environments that transform fragmented scientific data into actionable knowledge• Experimental Validation — patient-derived models and translational research capabilities that enable functional validation of AI-generated insightsTogether, these capabilities help researchers move beyond isolated datasets and disconnected workflows toward a more intelligent, data-driven approach to oncology research and development.Our mission is simple: help researchers make better decisions, faster, and ultimately improve outcomes for patients facing cancer.

• Series C
• 39 employees
• Founded 2016

Evox Therapeutics is harnessing and engineering the natural trafficking capabilities of extracellular vesicles to develop an entirely novel class of biotherapeutics.By combining groundbreaking exosome technology from well-renowned Oxford University and the Karolinska Institutet – the home of the Nobel Prize – we aim to revolutionise the treatment of a broad range of severe disease, with profound implications for human health.Based in Oxford, UK, Evox Therapeutics was founded in 2016 by Professor Matthew Wood of Oxford University, Assistant Professor Samir EL Andaloussi and Dr Per Lundin of the Karolinska Institutet, to capitalise on foundational intellectual property springing from the groundbreaking exosome research carried out in these two world-leading labs.Backed by Oxford Sciences Innovation and with a driven multidisciplinary team, Evox is building an exosome powerhouse focusing on the development of a modular platform for clinical translation of a broad range of exosome-based therapeutics.Evox Therapeutics has built a comprehensive intellectual property portfolio encompassing key aspects of EV-based nucleic acid and protein delivery technology. Coupled with targeting technology and proprietary manufacturing and purification methods, the company is set to develop transformational therapeutics across a wide range of disease areas, using an equally wide array of therapeutic modalities.

• Series C
• 36 employees
• Founded 2016

lululab is an AI based image analysis company that provides accurate analysis of user’s skin condition and tailored product & clinical program recommendation accordingly.lululab's analysis solution is available in both hardware form, which can be installed in H&B retail stores, clinics, spas, etc., and as an SDK that can be applied to the client's app/web, aiding users' skin management and improvement.With just single shot, it can analyze more than 7 different aspects of the skin within 10 seconds. It boasts an accuracy of over 92%, certified by professional evaluation agencies based on over 2 million skin data samples worldwide, and a reproducibility rate of 96%.For a detailed description of the solution, visit www.lulu-lab.com and you can also explore the LUMINI SDK Web Demo at https://bit.ly/lululabDEMO

• Series C
• 33 employees
• Founded 2017